Phialogics develops next‑generation biologics aimed at rebalancing the immune response in acute and chronic inflammation. Its current lead candidates are genetically engineered monospecific IgVs with the potential to be expanded to bispecific therapeutics to achieve selectivity for inflamed tissue and disease‑causing immune cells. The company intends to use the new funding to further develop its lead candidate in preclinical models and to compare performance against the current standard of care and other research approaches. Phialogics is led by CEO Dr. Andreas Ernst and operates in Basel, Switzerland and Heidelberg, Germany. The company is at the preclinical stage and focuses on engineered biologics for autoimmune indications to provide new solutions for patients with overactive immune responses.

Total raised

$1M

Funding rounds

1

Latest round

Seed

Latest activity

May 2023